<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01041963</url>
  </required_header>
  <id_info>
    <org_study_id>203/52</org_study_id>
    <nct_id>NCT01041963</nct_id>
  </id_info>
  <brief_title>The Effect of Enalapril and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients</brief_title>
  <official_title>The Effect of Enalapril and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, randomized, open-label, Single-center clinical trial to determine whether
      Enalapril or Enalapril plus Losartan effect on Peritoneal membrane transportation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed description:

      Many peritoneal dialysis patients suffer from uremia due to inadequate dialysis or volume
      overload caused by failure of peritoneal membrane transport.One of the most important
      etiologies of peritoneal membrane failure are unavoidable to use high glucose-containing
      dialysate solution that induce injury to mesothelial cell.Previous data found that injured
      mesothelial cell produces Angiotensin (Ang) II to induce peritoneal inflammation and
      fibrosis. Blockade of the renin-angiotensin system by angiotensin-converting enzyme
      inhibition(ACEI) or angiotensin receptor antagonism (ARB) play a major role to slow this
      effect.

      Although many trials in animal study have proved the benefit of ACEI and ARB in peritoneal
      membrane transport but clinical evidences in human are controversy. Up to now, all previous
      trials have limitation. First,The trials have small number of population(less than 20 in
      prospective randomized controlled trial). Second, The trials have multiple confounders on the
      study population because of the study include old case (that on peritoneal dialysis for many
      years) and new case (that just start treatment less than 1 year). Third, short duration of
      study(less than 3 months) to see the significant effect of RAAS blockade on peritoneal
      membrane transport. Forth, most study use dialysate albumin loss as an index of peritoneal
      membrane transport ,that less sensitivity to predict peritoneal membrane function. Fifth,no
      previous trials are attempted to study the effect of combination between ACEI and ARB.
      Therefore,we design to study the effect of both ACEI and ARB in a larger number of
      population, only in new case which are just recently found to be on peritoneal dialysis, our
      study is taken in longer duration and use both modified peritoneal equilibrium test and
      dialysate CA125 as an index of peritoneal membrane (physiology and anatomic index).This
      research will demonstrate efficacy of Enalapril and Losartan on Peritoneal membrane
      transportation lead to improve quality of life in CAPD patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">September 2010</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in dialysate CA-125 and modified peritoneal equilibrium test</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dialysis adequacy, residual renal function, hospitalization, peritonitis episodes, any adverse drug effects, death from any cause</measure>
    <time_frame>every 1 month, except for dialysis adequacy evaluate every 3 mo</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Continuous Ambulatory Peritoneal Dialysis</condition>
  <arm_group>
    <arm_group_label>Enalapril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Enalapril plus Losartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: antihypertensive agents, except ACE inhibitors and ARBs and spironolactone. Administration of antihypertensive agents will select as follows : CCB→β-blocker→α-blocker--&gt;hydralazine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril</intervention_name>
    <description>Patients with hypertension will take 20-40mg enalapril per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg</description>
    <arm_group_label>Enalapril</arm_group_label>
    <other_name>Anapril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril plus Losartan</intervention_name>
    <description>Patients with hypertension will take 20-40mg enalapril plus 25-50mg losartan per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg</description>
    <arm_group_label>Enalapril plus Losartan</arm_group_label>
    <other_name>Anapril plus Loranta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs and spironolactone. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All patients received CAPD more than 1 months but less than 1 year

          2. Subjects of either sex, more than 20 years old

          3. Hypertension

          4. Provision of written informed consent by subject or guardian

        Exclusion Criteria:

          1. No history of taking an ACE inhibitor or angiotensin-receptor blockers or aldosterone
             antagonist for at least 2 month

          2. Serum potassium more than 5.5 mEq/L

          3. History of renal artery stenosis

          4. Peritonitis or volume overload within the preceding 1 month

          5. Myocardial infarction within the preceding 6 months or clinically significant valvular
             disease or any active cardiovascular disease

          6. History of malignant hypertension or hypertensive encephalopathy or cerebrovascular
             accident within the preceding 6 months

          7. Any condition that may have precluded a patient from remaining in the study, such as
             alcohol or drug abuse, chronic liver disease, malignant disease, or psychiatric
             disorder

          8. History of allergy or intolerance to an ACE inhibitor or ARB

          9. Hypotension defined as systolic blood pressure less than 90 mmHg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Talerngsak Kanjanabuch, Assist. Prf.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chulalongkorn University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Talerngsak Kanjanabuch, Assist. Prf.</last_name>
    <phone>662-2564321</phone>
    <phone_ext>211</phone_ext>
    <email>golfnephro@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chulalongkorn university</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Talerngsak Kanjanabuch, Assist. Prf.</last_name>
      <phone>662-256-4321</phone>
      <phone_ext>211</phone_ext>
      <email>golfnephro@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Talerngsak Kanjanabuch, Assist. Prf.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wassawon Wontanatawatot, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2010</study_first_submitted>
  <study_first_submitted_qc>January 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2010</study_first_posted>
  <last_update_submitted>May 9, 2010</last_update_submitted>
  <last_update_submitted_qc>May 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Assist. Prf. Talerngsak Kanjanabuch, M.D / Department of nephrology, Division of Internal medicine, Faculty of medicine</name_title>
    <organization>Chulalongkorn University</organization>
  </responsible_party>
  <keyword>ACEI</keyword>
  <keyword>ARB</keyword>
  <keyword>CAPD</keyword>
  <keyword>Peritoneal membrane transport</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

